Registration to this Virtual Event is free of charge and gives you 180 days access. You will be sent details of how to access the event via email after registration.
For more information please click here.
| A UK Regulatory View on the Acceptability of Organ on a Chip Data David Jones, Queen's University of Belfast
I will give a UK Regulator’s view on the acceptability on in vitro data, especially data using human tissues and from organ on a chip assays.
| |
| A UK Regulatory View on the Acceptability of Organ on a Chip Data David Jones, Medicines and Healthcare Products Regulatory Agency
I will give a UK Regulator’s view on the acceptability on in vitro data, especially data using human tissues and from organ on a chip assays.
| |
| Can Organ-on-a-Chip Technology Really Replace Animal Testing of Drug and Chemical Safety? Kelly Davidge, Kirkstall Ltd
This presentation looks at the current limitations of organ-on-a-chip and explores how these challenges could be overcome through the use of intermediary, meso-scale technology.
| |
| Cancer Extravasation Dynamics in an In Vitro Blood Vessel Model Cristina Bertulli, University of Cambridge
The aim of this research is to investigate breast cancer extravasation in vitro, using a microfluidic system mimicking the 3D in vivo vascular microenvironment. This microfluidic platform can be used to quantify cancer cell morphological changes during the invasion process.
| |
| Kidney on a Chip using Cell Sheet Engineering Brian Derby, University of Manchester
There is a need for an improved kidney-on-a-chip for applications in toxicity testing and early stage compound screening. The filtration structures in a kidney are thin cell sheets that act as membranes. Here we present a cell sheet concept for a more accurate representation of a kidney for in vitro organ models.
| |
| Microfluidic Chips and Cancer Treatment John Greenman, The University Of Hull
The interdisciplinary lab on a chip group at the University of Hull have been characterizing and optimizing devices that can maintain fresh tissue biopsies in a functional state. This tissue can then be subjected to various “treatments” and the effects measured through analysis of the supernatant or post-treatment tissue. Results from varied tumour types and analyses will be presented.
| |
| Microfluidic Chips and Cancer Treatment John Greenman, The University Of Hull
The interdisciplinary lab on a chip group at the University of Hull have been characterizing and optimizing devices that can maintain fresh tissue biopsies in a functional state. This tissue can then be subjected to various “treatments” and the effects measured through analysis of the supernatant or post-treatment tissue. Results from varied tumour types and analyses will be presented.
| |
| Organ-on-a-chip – Are We There Yet? Lars Sundstrom, Elizabeth Blackwell Institute for Health Research, Bristol University
It was suggested over a decade ago that the ERA of Flat Biology (2D Tissue culture) would soon be over and that 3 dimensional ‘Organotypic’ systems would become the dominant in-vitro model for drug profiling. While we have made huge technical advances in methods of producing reliable 3D systems from both Stem Cells and Primary tissues these are not yet mainstream. Along with advances in microfluidics we could be equally bold and suggest the time has come for new ‘Organ on a Chip’ systems to replace in-vivo alternatives. In this presentation I’d like to explore translational aspects and explore where barriers still exist that might inhibit up take of such systems and prevent their widespread acceptance by the research community and by Industry.
| |
| Putting a Human Heart & Fat on a Chip: Microphysiological Platforms as in vitro Models of Cardiac and Adipose Tissue Peter Loskill, Eberhard Karls University Tübingen
Using microfabrication techniques we have developed two microphysiological platforms incorporating 3D in vitro models of human cardiac and adipose tissue in a microfluidic environment. Both organ-chips are able to create physiological micro-tissues that are viable and functional for multiple weeks.
| |
| The Patent Landscape of Organs-on-a-chip Robert Esmond, Sterne, Kessler, Goldstein & Fox P.L.L.C
The presentation will focus on ways to protect organs-on-a-chip innovation, patent filings directed to organs-on-a-chip technology, certain exceptions to patent infringement, as well as the possibility of future litigation.
| |
Back to the top
|